BIOMAT Database Logo BIOMAT Database Logo

[Subcutaneous administration of recombinant human erythropoietin (R-EPO) in the treatment of anemia in predialysis patients with chronic renal failure]. 1991

A Debska-Slizień, and B Rutkowski, and J Niemierko, and E Jankowska-Gan, and G Gołebiewska-Zurkowska, and J Kabata, and A Manitius
Kliniki Chorób Nerek Instytutu Chorób Wewnetrznych.

10 anemic (HB less than 9.0 g/dl) predialysis patients with chronic renal failure were treated for three months with s.c. administration of r-Epo. Blood morphological parameters were estimated using hematological autoanalyser Technicon H1. An increase of the mean hemoglobin (Hb) level from 8.39 to 10.57 g/dl was observed. In 8 patients Hb concentration after 3 months therapy ranged from 9.4 to 12.7 g/dl, but in the remaining two of them Hb was lower than 9.0 g/dl. Appearance of a high percentage of hypochromic erythrocytes is probably the most characteristic response to r-Epo treatment. This phenomenon was caused by iron deficiency. A significant increase of serum creatinine and BUN levels were observed in treated patients, without the concomitant decrease of endogenous creatinine clearance. No clinical symptoms suggesting deterioration of the renal function were observed. Subcutaneous therapy with r-Epo appeared an effective and convenient method of treatment of anemia in predialysis patients.

UI MeSH Term Description Entries
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D001806 Blood Urea Nitrogen The urea concentration of the blood stated in terms of nitrogen content. Serum (plasma) urea nitrogen is approximately 12% higher than blood urea nitrogen concentration because of the greater protein content of red blood cells. Increases in blood or serum urea nitrogen are referred to as azotemia and may have prerenal, renal, or postrenal causes. (From Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984) BUN,Nitrogen, Blood Urea,Urea Nitrogen, Blood
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D004921 Erythropoietin Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.
D005260 Female Females
D006454 Hemoglobins The oxygen-carrying proteins of ERYTHROCYTES. They are found in all vertebrates and some invertebrates. The number of globin subunits in the hemoglobin quaternary structure differs between species. Structures range from monomeric to a variety of multimeric arrangements. Eryhem,Ferrous Hemoglobin,Hemoglobin,Hemoglobin, Ferrous

Related Publications

A Debska-Slizień, and B Rutkowski, and J Niemierko, and E Jankowska-Gan, and G Gołebiewska-Zurkowska, and J Kabata, and A Manitius
Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin.
October 1990, The American journal of medicine,
A Debska-Slizień, and B Rutkowski, and J Niemierko, and E Jankowska-Gan, and G Gołebiewska-Zurkowska, and J Kabata, and A Manitius
[The effect of low doses of recombinant human erythropoietin on renal anemia in predialysis patients with chronic renal failure].
July 1993, Zhonghua nei ke za zhi,
A Debska-Slizień, and B Rutkowski, and J Niemierko, and E Jankowska-Gan, and G Gołebiewska-Zurkowska, and J Kabata, and A Manitius
The effect of subcutaneous recombinant human erythropoietin (r-Hu EPO) in CAPD patients with renal anaemia.
January 1994, Annales Universitatis Mariae Curie-Sklodowska. Sectio D: Medicina,
A Debska-Slizień, and B Rutkowski, and J Niemierko, and E Jankowska-Gan, and G Gołebiewska-Zurkowska, and J Kabata, and A Manitius
[Anaemia treatment with recombinant human erythropoietin in predialysis patients with chronic renal failure--own experience].
October 2003, Polskie Archiwum Medycyny Wewnetrznej,
A Debska-Slizień, and B Rutkowski, and J Niemierko, and E Jankowska-Gan, and G Gołebiewska-Zurkowska, and J Kabata, and A Manitius
[Recombinant human erythropoietin (r-Hu-EPO) in the treatment of nephrogenic anemia].
November 1988, Polskie Archiwum Medycyny Wewnetrznej,
A Debska-Slizień, and B Rutkowski, and J Niemierko, and E Jankowska-Gan, and G Gołebiewska-Zurkowska, and J Kabata, and A Manitius
Recombinant human erythropoietin for anaemia associated with chronic renal failure in predialysis patients.
January 1992, Przeglad lekarski,
A Debska-Slizień, and B Rutkowski, and J Niemierko, and E Jankowska-Gan, and G Gołebiewska-Zurkowska, and J Kabata, and A Manitius
[Treatment of non-renal anemia with human recombinant erythropoietin (rHU-EPO].
January 1996, Przeglad lekarski,
A Debska-Slizień, and B Rutkowski, and J Niemierko, and E Jankowska-Gan, and G Gołebiewska-Zurkowska, and J Kabata, and A Manitius
Hemodynamic effects of anemia correction by recombinant human erythropoietin in predialysis patients with renal failure.
January 2005, Renal failure,
A Debska-Slizień, and B Rutkowski, and J Niemierko, and E Jankowska-Gan, and G Gołebiewska-Zurkowska, and J Kabata, and A Manitius
Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients.
November 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation,
A Debska-Slizień, and B Rutkowski, and J Niemierko, and E Jankowska-Gan, and G Gołebiewska-Zurkowska, and J Kabata, and A Manitius
Treatment of the anemia of chronic renal failure with recombinant human erythropoietin.
January 1990, Annual review of medicine,
Copied contents to your clipboard!